All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.
The AML Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
The AML Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the AML Hub cannot guarantee the accuracy of translated content. The AML Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
What is the clinical significance of secondary-AML-type mutations in de novo AML?
Featured
During the EHA 2022 Congress, the AML Hub spoke with Isolda Fernandez, FUNDALEU, Buenos Aires, AR. We asked, What is the clinical significance of secondary-AML-type mutations in de novo AML?
What is the clinical significance of secondary-AML-type mutations in de novo AML
Fernandez discusses the importance of the identification of AML mutations and the prognostic effects on patients (e.g., NPM1 and TP53 mutations). Fernandez outlines the incidence of mutations, and discusses a presentation from the EHA 2022 Congress about clinical and prognostic implications of secondary-AML-type mutations in de novo patients with AML.
Related articles
Newsletter
Subscribe to get the best content related to AML delivered to your inbox